Galvin Gaustad & Stein’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22M Sell
1,324
-23
-2% -$23.3K 0.1% 116
2025
Q4
$1.45M Buy
1,347
+151
+13% +$144K 0.11% 103
2025
Q3
$913K Sell
1,196
-67
-5% -$49.9K 0.07% 115
2025
Q2
$984K Sell
1,263
-311
-20% -$242K 0.08% 102
2025
Q1
$1.3M Sell
1,574
-194
-11% -$161K 0.12% 88
2024
Q4
$1.36M Sell
1,768
-53
-3% -$43.9K 0.12% 86
2024
Q3
$1.61M Sell
1,821
-133
-7% -$120K 0.14% 79
2024
Q2
$1.77M Sell
1,954
-73
-4% -$58.4K 0.16% 72
2024
Q1
$1.58M Sell
2,027
-483
-19% -$344K 0.15% 77
2023
Q4
$1.46M Sell
2,510
-105
-4% -$61.3K 0.14% 77
2023
Q3
$1.4M Sell
2,615
-72
-3% -$37.1K 0.14% 78
2023
Q2
$1.26M Sell
2,687
-74
-3% -$31K 0.12% 81
2023
Q1
$948K Sell
2,761
-936
-25% -$316K 0.09% 88
2022
Q4
$1.35M Sell
3,697
-882
-19% -$313K 0.14% 79
2022
Q3
$1.48M Sell
4,579
-97
-2% -$30.7K 0.16% 84
2022
Q2
$1.52M Sell
4,676
-746
-14% -$224K 0.15% 84
2022
Q1
$1.55M Sell
5,422
-464
-8% -$119K 0.14% 88
2021
Q4
$1.63M Buy
5,886
+89
+2% +$22.6K 0.14% 92
2021
Q3
$1.34M Sell
5,797
-1,628
-22% -$402K 0.13% 93
2021
Q2
$1.7M Sell
7,425
-381
-5% -$76.5K 0.16% 89
2021
Q1
$1.46M Sell
7,806
-524
-6% -$102K 0.15% 95
2020
Q4
$1.41M Buy
+8,330
New +$1.24M 0.15% 96

Other funds holding LLY

Galvin Gaustad & Stein's LLY Position: Q1 2026 in Review

Galvin Gaustad & Stein reduced its Eli Lilly (LLY) stake by 1.7% in Q1 2026, selling an estimated $23.3K and leaving 1,324 shares worth $1.22M. The position accounts for 0.1% of the portfolio, ranked #116.

Galvin Gaustad & Stein first reported a position in LLY in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.77M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Galvin Gaustad & Stein held 1,324 shares of Eli Lilly worth $1.22M as of Q1 2026.
  • Galvin Gaustad & Stein sold 23 Eli Lilly shares in Q1 2026, an estimated $23.3K.
  • Eli Lilly made up 0.1% of Galvin Gaustad & Stein's portfolio in Q1 2026, its #116 holding.
  • Galvin Gaustad & Stein first reported a position in Eli Lilly in Q4 2020 and has held it in 22 quarters since.
  • Galvin Gaustad & Stein's Eli Lilly position peaked at $1.77M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Galvin Gaustad & Stein's 13F filing for Q1 2026, filed 14 May 2026.